A previous report demonstrated that BMS-986020, a first-generation LPA1 antagonist, significantly slowed FVC decline compared with placebo in a phase 2 clinical trial in patients with IPF [15]. The gene discussed is LPAR1; the disease is idiopathic pulmonary fibrosis.